Amneal Pharmaceuticals (AMRX) Price & Analysis

Compare

555 Followers

AMRX Stock Chart & Stats

Day’s Range― - ―

52-Week Range$6.69 - $9.79

Previous CloseN/A

Volume380.73K

Average Volume (3M)1.53M

Market Cap

$2.95B

Enterprise Value$5.17B

Total Cash (Recent Filing)$81.19M

Total Debt (Recent Filing)$2.58B

Price to Earnings (P/E)1465.6

Beta0.93

Next Earnings

Nov 07, 2025

EPS Estimate

0.16

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.25

Shares Outstanding314,079,300

10 Day Avg. Volume1,736,754

30 Day Avg. Volume1,533,507

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap1.76

Enterprise Value/Revenue1.81

Enterprise Value/Gross Profit4.81

Enterprise Value/Ebitda8.86

Forecast

1Y Price Target

$11.67

Price Target Upside24.41% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering3

Bulls Say, Bears Say

Bulls Say

Business PositioningAMRX's generics business is increasingly well-positioned with a portfolio more focused on complex products and biosimilars, supporting sustainable growth over the next several years.

Product LaunchWith the Crexont launch off to a solid start and continued momentum elsewhere across the portfolio, analyst upgrades AMRX to OW from N.

Bears Say

Market CautionThere is a more mixed view on Crexont and more caution than the Street on overall Gx fundamentals longer-term.

Amneal Pharmaceuticals News

Knight Therapeutics announces CREXONT regulatory submission in Mexico

Knight Therapeutics (KHTRF) announced that its Mexican affiliate, Grupo Biotoscana de Especialidad, has submitted a marketing authorization application...

23d ago

AMRX

Amneal Pharma Reports Strong Q2 2025 Results

Amneal Pharma ( ($AMRX) ) has released its Q2 earnings. Here is a breakdown of the information Amneal...

22d ago

AMRX

Amneal Pharma’s Optimistic Q2 Earnings Call Highlights

Amneal Pharma (($AMRX)) has held its Q2 earnings call. Read on for the main highlights of the call....

22d ago

AMRX

Amneal Pharmaceuticals Reports Strong Q2 2025 Results

Amneal Pharmaceuticals ( ($AMRX) ) just unveiled an announcement. Amneal Pharmaceuticals reported strong financial results for the second...

23d ago

AMRX

Amneal Pharmaceuticals Secures $2.1 Billion in Loans

An announcement from Amneal Pharmaceuticals ( ($AMRX) ) is now available. On August 1, 2025, Amneal Pharmaceuticals LLC,...

27d ago

AMRX

Amneal Pharmaceuticals Prices $600M Senior Notes Offering

Amneal Pharmaceuticals ( ($AMRX) ) has issued an announcement. On July 24, 2025, Amneal Pharmaceuticals announced that its...

1M ago

AMRX

Amneal Pharmaceuticals Seeks $1.8 Billion in New Loans

Amneal Pharmaceuticals ( ($AMRX) ) has shared an update. On July 21, 2025, Amneal Pharmaceuticals announced that its...

1M ago

AMRX

Amneal Pharmaceuticals Board Restructuring Amidst Financial Growth

Amneal Pharmaceuticals ( ($AMRX) ) just unveiled an update. Amneal Pharmaceuticals announced a reduction in its Board of...

1M ago

AMRX

Amneal Pharmaceuticals sees Q2 revenue $720M-$730M, consensus $753.34M

Adjusted EBITDA of $180M to $185M, an increase of approximately 13% versus the same period in 2024. Gross...

1M ago

AMRX

Amneal Pharmaceuticals announces proposed refinancing of credit agreement

Amneal Pharmaceuticals (AMRX) announced that its subsidiary, Amneal Pharmaceuticals is seeking to borrow $1.8B aggregate principal amount of...

1M ago

AMRX

Knight Therapeutics announces CREXONT NDS accepted for Health Canada review

Knight Therapeutics (KHTRF) announced that Knight’s New Drug Submission for CREXONT has been accepted for review by Health...

1M ago

AMRX

Amneal Pharmaceuticals announces results from trial evaluating ADL-018

Amneal Pharmaceuticals (AMRX) highlighted positive topline results from a confirmatory clinical efficacy and safety clinical trial evaluating ADL-018,...

2M ago

AMRX

Amneal Pharmaceuticals receives U.S. FDA approval for prednisolone acetate

Amneal Pharmaceuticals (AMRX) announced the U.S. Food and Drug Administration, FDA, approval of prednisolone acetate ophthalmic suspension, 1%...

3M ago

AMRX

Amneal Pharmaceuticals initiated with a Buy at Goldman Sachs

Goldman Sachs analyst Matt Dellatorre initiated coverage of Amneal Pharmaceuticals (AMRX) with a Buy rating and $12 price...

3M ago

AMRX

AMRX FAQ

What was Amneal Pharmaceuticals Inc’s price range in the past 12 months?

Amneal Pharmaceuticals Inc lowest stock price was $6.68 and its highest was $9.79 in the past 12 months.

What is Amneal Pharmaceuticals Inc’s market cap?

Amneal Pharmaceuticals Inc’s market cap is $2.95B.

When is Amneal Pharmaceuticals Inc’s upcoming earnings report date?

Amneal Pharmaceuticals Inc’s upcoming earnings report date is Nov 07, 2025 which is in 71 days.

How were Amneal Pharmaceuticals Inc’s earnings last quarter?

Amneal Pharmaceuticals Inc released its earnings results on Aug 05, 2025. The company reported $0.25 earnings per share for the quarter, beating the consensus estimate of $0.175 by $0.075.

Is Amneal Pharmaceuticals Inc overvalued?

According to Wall Street analysts Amneal Pharmaceuticals Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Amneal Pharmaceuticals Inc pay dividends?

Amneal Pharmaceuticals Inc does not currently pay dividends.

What is Amneal Pharmaceuticals Inc’s EPS estimate?

Amneal Pharmaceuticals Inc’s EPS estimate is 0.16.

How many shares outstanding does Amneal Pharmaceuticals Inc have?

Amneal Pharmaceuticals Inc has 314,079,300 shares outstanding.

What happened to Amneal Pharmaceuticals Inc’s price movement after its last earnings report?

Amneal Pharmaceuticals Inc reported an EPS of $0.25 in its last earnings report, beating expectations of $0.175. Following the earnings report the stock price went up 2.136%.

Which hedge fund is a major shareholder of Amneal Pharmaceuticals Inc?

Currently, no hedge funds are holding shares in AMRX

Amneal Pharmaceuticals Stock Smart Score

Underperform

Fundamentals

Return on Equity

106.97%

Trailing 12-Months

Asset Growth

-2.48%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Amneal Pharmaceuticals Inc

Amneal Pharmaceuticals, Inc. is a global pharmaceutical company based in the United States that specializes in the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The company operates primarily in the prescription drug market and focuses on various therapeutic areas, including central nervous system, infectious disease, endocrinology, and pain management. Amneal's portfolio includes a wide range of generic medications, as well as proprietary branded products, positioning it as a significant player in the pharmaceutical industry.

Amneal Pharmaceuticals (AMRX) Earnings & Revenues

Historic Earnings Reports

AMRX Company Deck

AMRX Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

Amneal's earnings call reflected strong financial performance and growth prospects, with successful product launches and strategic debt refinancing. Despite some challenges in specific segments, the overall outlook remains positive.View all AMRX earnings summaries

AMRX Stock 12 Month Forecast

Average Price Target

$11.67

▲(24.41% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"6":"$6","8":"$8","10":"$10","12":"$12","14":"$14"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":13,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$13.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":11.67,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$11.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$10.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[6,8,10,12,14],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.83,8.227692307692308,8.625384615384615,9.023076923076923,9.420769230769231,9.818461538461538,10.216153846153846,10.613846153846154,11.01153846153846,11.409230769230769,11.806923076923077,12.204615384615384,12.602307692307692,{"y":13,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.83,8.125384615384615,8.420769230769231,8.716153846153846,9.01153846153846,9.306923076923077,9.602307692307692,9.897692307692306,10.193076923076923,10.48846153846154,10.783846153846154,11.079230769230769,11.374615384615385,{"y":11.67,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.83,7.996923076923077,8.163846153846153,8.330769230769231,8.497692307692308,8.664615384615384,8.831538461538461,8.99846153846154,9.165384615384616,9.332307692307692,9.499230769230769,9.666153846153847,9.833076923076923,{"y":10,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":7.18,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.66,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.7,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.49,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.57,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.92,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.26,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.67,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.23,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.74,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.42,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.21,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.83,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >